|
|
|
Enlyton clinicians and scientists are leaders in their respective fields; recent publications that reflect the substance of their research and relevance to the science of Enlyton.
Songji Zhao, Yuji Kuge, Masashi Kohanawa, Toshiyuki Takahashi, Yan Zhao, Min Yi, Kakuko Kanegae, Koh-ichi Seki, and Nagara Tamaki, Usefulness of 11C-Methionine for Differentiating Tumors from Granulomas in Experimental Rat Models: A Comparison with 18F-FDG and 18F-FLT. J Nucl Med 2008; 49:135–141
Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008 Mar; 29(3): 193-207
Duxin Sun, Mark Bloomston, George Hinkle, Osama Habib Al-Saif, Nathan C. Hall, Stephen P. Povoski, Mark W. Arnold, Edward W. Martin, Jr., Radioimmunoguided Surgery (RIGS), PET/CT, Image-Guided Surgery, and Fluorescence Image-Guided Surgery: Past, Present and Future. Journal of Surgical Oncology 2007: 96: 297-308.
Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med. 2007 Nov; 37(6):400-19
Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007 Apr;8(4):279-81.
Memorial Sloan-Kettering Phase I PET imaging trial involving the use of a whole antibody conjugated to 124I generated excellent images from initial patient scans – intense localization of the radiolabeled antibody in the tumor with very little tissue uptake.
[Presently in a multicenter Phase III trial]
Belhocine T, Spaegen K, Dusart M, Castaigne C, Muylle K, Bourgeois D, Dierickx L, Flamen P. 18FDG PET in oncology: the best and the worst (Review). Int J Oncol. 2006 May; 28(5): 1249-61.
Jim Xiao, Sara Horst, George Hinkle, Xianhua Cao, Ergun Kocak, Jing Fang, Donn Young, M. Khazaeli, Doreen Agnese, Duxin Sun, and Edward Martin, Jr. Pharmacokinetics and Clinical Evaluation of 125I-Radiolabeled Humanized CC49 Monoclonal Antibody (HuCC49ΔCH2) in Recurrent and Metastatic Colorectal Cancer Patients. Cancer Biotherapy and Radiopharmaceuticals 2005: 20(1); 16-25
Doreen M. Agnese, MD, Shahab F. Abdessalam, MD, William E. Burak, Jr., MD, Mark W. Arnold, MD, Denise Soble, RN, George H. Hinkle, RPh, Donn Young, PhD, M.B. Khazaeli, PhD, and Edward W. Martin, Jr. MD. Pilot Study Using a Humanized CC49 Monoclonal Antibody (HuCC49ΔCH2) to Localize Recurrent Colorectal Carcinoma. Annals of Surgical Oncology, 2004. 11(2): 197-202.
|
| |
|